Evaluation of Mortality During Long-Term Treatment with Tafamidis for Transthyretin Amyloidosis with Polyneuropathy: Clinical Trial Results up to 8.5 Years

Introduction: The effects of tafamidis on mortality in Val30Met and non-Val30Met patients with transthyretin amyloidosis with polyneuropathy (ATTR-PN) were evaluated. Methods: The analyses were based on cumulative data from the Val30Met patients in the 18-month double-blind registration study and it...

ver descrição completa

Detalhes bibliográficos
Autor principal: Merlini, Giampaolo (author)
Outros Autores: Coelho, Teresa (author), Waddington Cruz, Márcia (author), Li, Huihua (author), Stewart, Michelle (author), Ebede, Ben (author)
Formato: article
Idioma:eng
Publicado em: 2022
Assuntos:
Amyloidosis; Mortality
Polyneuropathy
Tafamidis
Transthyretin
Val30Met
Texto completo:http://hdl.handle.net/10400.16/2685
País:Portugal
Oai:oai:repositorio.chporto.pt:10400.16/2685

Texto Completo

http://hdl.handle.net/10400.16/2685

Registos relacionados